REG-Bioventix Plc: Notice of AGM and Posting of Annual Report <Origin Href="QuoteRef">BVXP.L</Origin>

BioventixAnnouncement

24/11/2014 14:57

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                  Notice of AGM and Posting of Annual Report                   

Bioventix plc (AIM: BVXP) announces that its Annual General Meeting will be
held at 7 Romans Business Park, Farnham GU9 7SX at 3.30 p.m. on Wednesday 
3 December 2014.

Copies of the 2014 Annual Report and the Notice of the Annual General Meeting
have been sent to shareholders and are also available on the Company's website
at www.bioventix.com.

For further information please contact:

Bioventix plc              Chief Executive Officer    Tel: 01252 728 001       
Peter Harrison                                                                 
                                                                               
finnCap Ltd                Corporate Finance          Tel: 020 7220 0500       
Geoff Nash/Simon Hicks     Corporate Broking                                   
Steve Norcross                                                                 

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



END



Copyright © 2014 PR Newswire Association, LLC. All Rights Reserved